Vertex Announces US FDA Approval of CASGEVY™ …
Jan 16, 2024 · BOSTON -- (BUSINESS WIRE)--Jan. 16, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the U.S. Food and Drug Administration …
Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY
Dec 8, 2023 · Vertex has submitted a BLA to the U.S. FDA for the potential use of CASGEVY for patients 12 years and older with TDT and has been assigned a Prescription Drug User Fee …
Vertex Presents Positive Long-Term Data On CASGEVY™ …
Dec 8, 2024 · BOSTON--(BUSINESS WIRE)--Dec. 8, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced longer-term data for CASGEVY™ …
CASGEVY is an autologous genome edited hematopoietic stem cell-based gene therapy indicated for the treatment of sickle cell disease (SCD) in patients 12 years and older with …
HCP Official Website for CASGEVY® (exagamglogene autotemcel)
CASGEVY is indicated for the treatment of patients aged 12 years and older with: Monitor absolute neutrophil counts (ANC) and manage infections according to standard guidelines and …
CASGEVY | FDA - U.S. Food and Drug Administration
Manufacturer: Vertex Pharmaceuticals Incorporated Indication: STN 125787 - Treatment of sickle cell disease (SCD) in patients 12 years and older with recurrent vaso occlusive crises (VOCs).
Long-term data shows durability of Vertex's gene therapy Casgevy
Jun 14, 2024 · Six months after Vertex earned a historic FDA approval for sickle cell disease (SCD) gene therapy Casgevy (exa-cel), long-term data is beginning to show the consistent …
FDA approves Vertex, CRISPR's Casgevy for beta-thalassemia
Jan 16, 2024 · Vertex Pharmaceuticals and CRISPR Therapeutics have scored an FDA approval for their gene-editing therapy Casgevy (exa-cel) to treat transfusion-dependent beta …
Press Release - Vertex Pharmaceuticals Newsroom
Nov 16, 2023 · In two global clinical trials of CASGEVY in SCD and TDT, the trials met their respective primary outcome of becoming free from severe VOCs or transfusion independent …
FDA widens approval of Vertex’s CRISPR medicine to treat beta ...
Jan 16, 2024 · The Food and Drug Administration on Tuesday approved Vertex Pharmaceuticals’ CRISPR-based medicine Casgevy for the inherited blood condition beta thalassemia, …
- Some results have been removed